159 related articles for article (PubMed ID: 38508330)
1. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives.
Cymbal M; Chatterjee A; Baggott B; Auron M
Am J Med; 2024 Jul; 137(7):571-576. PubMed ID: 38508330
[TBL] [Abstract][Full Text] [Related]
2. Therapeutics for
Khanna S; Voth E
Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
[TBL] [Abstract][Full Text] [Related]
3. Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease.
Ramesh MS; Yee J
Adv Chronic Kidney Dis; 2019 Jan; 26(1):30-34. PubMed ID: 30876614
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
5. Review article: The epidemiology and management of Clostridioides difficile infection-A clinical update.
Clarke LM; Allegretti JR
Aliment Pharmacol Ther; 2024 Jun; 59(11):1335-1349. PubMed ID: 38534216
[TBL] [Abstract][Full Text] [Related]
6. Clostridioides Difficile: A Concise Review of Best Practices and Updates.
Yakout A; Bi Y; Harris DM
J Prim Care Community Health; 2024; 15():21501319241249645. PubMed ID: 38726585
[TBL] [Abstract][Full Text] [Related]
7. Treatment of
Oksi J; Anttila VJ; Mattila E
Ann Med; 2020; 52(1-2):12-20. PubMed ID: 31801387
[No Abstract] [Full Text] [Related]
8. Evolving Strategies to Manage Clostridium difficile Colitis.
Bowman JA; Utter GH
J Gastrointest Surg; 2020 Feb; 24(2):484-491. PubMed ID: 31768834
[TBL] [Abstract][Full Text] [Related]
9.
Mullish BH; Williams HR
Clin Med (Lond); 2018 Jun; 18(3):237-241. PubMed ID: 29858434
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
11. Clostridioides difficile Colitis.
Pumiglia L; Wilson L; Rashidi L
Surg Clin North Am; 2024 Jun; 104(3):545-556. PubMed ID: 38677819
[TBL] [Abstract][Full Text] [Related]
12. Fighting against Clostridioides difficile infection: Current medications.
Quan M; Zhang X; Fang Q; Lv X; Wang X; Zong Z
Int J Antimicrob Agents; 2024 Jul; 64(1):107198. PubMed ID: 38734214
[TBL] [Abstract][Full Text] [Related]
13. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
14. [Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile].
Beneš J; Stebel R; Musil V; Krůtová M; Vejmelka J; Kohout P
Klin Mikrobiol Infekc Lek; 2022 Sep; 28(3):77-94. PubMed ID: 36791303
[TBL] [Abstract][Full Text] [Related]
15. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
[TBL] [Abstract][Full Text] [Related]
16. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Clostridium difficile infection treated with bezlotoxumab in a liver transplant patient.
Hernández M; Saura N; García S; Velamazán R; Abad D; Hijos G; Alfaro E; Cañamares P; Laredo V; Lorente S
Gastroenterol Hepatol; 2021 Dec; 44(10):720-721. PubMed ID: 33199130
[No Abstract] [Full Text] [Related]
18. Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.
Escudero-Sanchez R; Muriel García A; García Fernández S; Valencia Alijo A; Tasias Pitarch M; Merino De Lucas E; Gutierrez Rojas A; Ramos Martínez A; Salavert Lletí M; Giner L; Ruíz Ruigomez M; García Basas L; Fernández Fradejas J; Olmedo Sampedrio M; Cano Yuste A; Díaz Pollán B; Rodríguez Hernández MJ; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez B; Rodríguez-Pardo D; De La Torre Cisneros J; López Medrano F; Cobo Reinoso J
J Antimicrob Chemother; 2022 Jun; 77(7):1996-2002. PubMed ID: 35403189
[TBL] [Abstract][Full Text] [Related]
19. [Clostridioides difficile: updated recommendations].
Barbut F; Eckert C; Lalande V; Le Neindre K; Couturier J
Rev Prat; 2022 Sep; 72(7):703-709. PubMed ID: 36511953
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.
Rao K; Malani PN
JAMA; 2020 Apr; 323(14):1403-1404. PubMed ID: 32150234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
